Global Favipiravir Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Favipiravir Market Research Report 2024
Favipiravir, sold under the brand name Avigan, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections. Like the experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensend API for it to Zhejiang Hisun Pharmaceutical Co. of China. It became a generic drug in 2019.
According to Mr Accuracy reports’s new survey, global Favipiravir market is projected to reach US$ 11 million in 2034, increasing from US$ 342.8 million in 2022, with the CAGR of -22.0% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Favipiravir market research.
In the global Favipiravir market, ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma are the key players. The global 5 Largest Favipiravir Players account for 70% market share by revenue. India hold a key market revenue share of the Favipiravir market which account for 73%. The classification of Favipiravir includes Brand Drug and Generic Drug. Brand Drug accounted for a share of 16% in the global Favipiravir market. Favipiravir is widely used for Influenza Viruses, COVID-19, etc. The most proportion of Favipiravir is used for COVID-19 and the proportion is 97%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Favipiravir market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm
Segment by Type
Brand Drug
Generic Drug
Influenza Viruses
COVID-19
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Favipiravir report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Favipiravir market is projected to reach US$ 11 million in 2034, increasing from US$ 342.8 million in 2022, with the CAGR of -22.0% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Favipiravir market research.
In the global Favipiravir market, ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma are the key players. The global 5 Largest Favipiravir Players account for 70% market share by revenue. India hold a key market revenue share of the Favipiravir market which account for 73%. The classification of Favipiravir includes Brand Drug and Generic Drug. Brand Drug accounted for a share of 16% in the global Favipiravir market. Favipiravir is widely used for Influenza Viruses, COVID-19, etc. The most proportion of Favipiravir is used for COVID-19 and the proportion is 97%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Favipiravir market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm
Segment by Type
Brand Drug
Generic Drug
Segment by Application
Influenza Viruses
COVID-19
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Favipiravir report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source